Trial NCT04955626
Publication Moreira E D, N Engl J Med, 2022
Primary outcome on the report: 1) Incidence of adverse events and serious adverse events; 2) Effectiveness of the BNT162b2 vaccine against laboratory-confirmed Covid-19 beginning at least 7 days after the administration of dose 3

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.